Cost-effectiveness of liver cancer screening

Abstract Screening for primary liver cancer means surveillance for hepatocellular carcinoma (HCC), which is one of the most common cancers worldwide. Detection of HCC for curative treatment is increased by surveillance, but target population, optimal periodicity and cost-effectiveness aspects are st...

Full description

Saved in:
Bibliographic Details
Published in:Baillière's best practice & research. Clinical gastroenterology 2013-12, Vol.27 (6), p.961-972
Main Authors: Cucchetti, Alessandro, MD, Cescon, Matteo, MD, Erroi, Virginia, MD, Pinna, Antonio D., MD
Format: Article
Language:English
Subjects:
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - economics
Carcinoma, Hepatocellular - pathology
Cirrhosis
Clinical trials
Cost-benefit
Cost-Benefit Analysis
Cost-effectiveness
Costs
Early Detection of Cancer - economics
Gastroenterology and Hepatology
Growth models
Health Care Costs
Hepatitis
Hepatocellular carcinoma
Humans
Infections
Liver - pathology
Liver cancer
Liver cirrhosis
Liver diseases
Liver Neoplasms - diagnosis
Liver Neoplasms - economics
Liver Neoplasms - pathology
Medical screening
Mortality
Patients
Prevention & control
Screening
Surveillance
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Screening for primary liver cancer means surveillance for hepatocellular carcinoma (HCC), which is one of the most common cancers worldwide. Detection of HCC for curative treatment is increased by surveillance, but target population, optimal periodicity and cost-effectiveness aspects are still debated issues. The aim of surveillance is to obtain a reduction in HCC-related mortality and this is usually achieved through an early diagnosis that increases both applicability and cost-effectiveness of curative treatments. The aim of the present review is to analyse economic aspects of HCC surveillance. Articles that assessed cost-effectiveness of surveillance for HCC, published between 1996 and February 2013, were reviewed in order to verify the cost-effectiveness of surveillance, its optimal periodicity, the target population and the role of alternative surveillance strategies. International guidelines are currently based on the results of such cost-effectiveness analyses, highlighting the importance of the release of cost-effectiveness-guided guidelines for HCC management.
ISSN:1521-6918
1532-1916
DOI:10.1016/j.bpg.2013.08.021